ReviewBioactive materials2022
Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: From intrinsic physicochemical properties to external modification.
Review in Bioactive materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed.
- Sequentially Responsive Three-Lobed Supramolecular Platform for Tumor Microenvironment Remodeling and Blood-Brain Barrier Penetration.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Self-assembled supramolecular nanoparticles ofActa pharmaceutica Sinica. B · 2026Article
- Carrier-free self-assembled nanoparticles derived from traditional Chinese medicine active components: construction strategies and applications.RSC advances · 2026Review
- Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.Discover nano · 2026Review
- Machine learning reshapes the paradigm of nanomedicine research.Acta pharmaceutica Sinica. B · 2026Review
- A Computational Strategy for Identifying Self-Assembling Food-Derived Molecules for Antiparasitic Nanotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cationic lipid-based nanoparticles for therapeutic delivery in cancer treatment: physicochemical characteristics, therapeutic cargos, and clinical potential.Applied microscopy · 2026Review
- Self-assembled nanoplatforms for cancer immunotherapy: Principles, progress and perspectives.Acta pharmaceutica Sinica. B · 2026Review
- Heterocyclic modified paclitaxel prodrug nanoassemblies for stimuli-responsive deliveryActa pharmaceutica Sinica. B · 2026Article
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Self-carrier nanodrugs with dual antibacterial agents to overcome tobramycin resistance in multidrug-resistantBioactive materials · 2026Article
- Traditional Chinese Medicine Modernization in Diagnosis and Treatment: Utilizing Artificial Intelligence and Nanotechnology.MedComm · 2026Review
- Advances in Drug Delivery Systems Utilizing Glycyrrhizic Acid and Its Aglycone Glycyrrhetinic Acid in Cancer Therapy.International journal of nanomedicine · 2026Review
- Design of prodrugs with reactive oxygen species as activators and their application in tumor therapy.Theranostics · 2026Review
- Beyond Glucose and Lipids: The Pivotal Role of Amino Acid Reprogramming in Shaping the Tumor Microenvironment and Guiding the Development of Novel Therapeutics.International journal of medical sciences · 2026Review
- Intranasal Delivery of Curcumin-Loaded Pure Drug Self-Assembled Lipid-Based Nanoparticles for Targeted Therapy of Depression.International journal of nanomedicine · 2026Article
- Machine-Learning-Accelerated Design of Ternary Carrier-Free Nanomedicine for Intranasal Therapy of Brain Metastatic Non-small-cell Lung Cancer.Research (Washington, D.C.) · 2026Article
- Carrier-free nanoparticles based on natural products trigger dual "synergy and attenuation" for enhanced phototherapy of liver cancer.Materials today. Bio · 2025Article
- Fluorinated prodrug-engineered nano-remodeler relieves tumor hypoxia for dual-enhanced ferroptosis-immunotherapy.Cell reports. Medicine · 2025Article
- Synergistic anticancer effects of carrier-free self-assembled doxorubicin and emodin nanoparticles in non-small cell lung cancer.Scientific reports · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The considerable development of carrier-free nanodrugs has been achieved due to their high drug-loading capability, simple preparation method, and offering "all-in-one" functional platform features. However, the native defects of carrier-free nanodrugs limit their delivery and release behavior throughout the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.